Moderna shares fall as much as 10%, down 26% over two days

The significance here is the scale of the move—a 26% two-session slide is a violent repricing, and the absence of an identified catalyst in the material is itself notable, since it leaves the selloff without a clear fundamental explanation. The move affects holders of the stock and anyone tracking sentiment around vaccine makers, but without a stated cause the read-through beyond Moderna is limited. The open question is whether a catalyst emerges to explain the decline or whether it remains an unexplained sentiment shock—that, rather than the headline number, is what would determine if the move carries broader signal.